These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18681195)

  • 1. Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies.
    Tedaldi EM
    J Addict Dis; 2008; 27(2):83-91. PubMed ID: 18681195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical management of drug addicts infected with human immunodeficiency virus and hepatitis C virus.
    Khalsa JH; Vocci F
    J Addict Dis; 2008; 27(2):1-10. PubMed ID: 18681186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of acute and chronic HCV infection in persons with HIV coinfection.
    Sulkowski MS
    J Hepatol; 2014 Nov; 61(1 Suppl):S108-19. PubMed ID: 25443339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elvitegravir: a once daily alternative to raltegravir.
    Desimmie BA; Schrijvers R; Debyser Z
    Lancet Infect Dis; 2012 Jan; 12(1):3-5. PubMed ID: 22015078
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
    Genebat M; Ruiz-Mateos E; Pulido I; González-Serna A; García-Pergañeda A; Méndez G; Romero-Sánchez MC; Ferrando-Martínez S; Leal M
    Curr HIV Res; 2010 Sep; 8(6):482-6. PubMed ID: 20642436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
    Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management.
    Verucchi G; Calza L; Manfredi R; Chiodo F
    Infection; 2004 Feb; 32(1):33-46. PubMed ID: 15007741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hepatitis C and HIV in Spanish prisons].
    Soriano V; González-Lahoz J
    Enferm Infecc Microbiol Clin; 2005 Feb; 23(2):51-2. PubMed ID: 15743572
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
    Neuman MG; Monteiro M; Rehm J
    Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
    Chen SH; Tan SL
    Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
    Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
    Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
    West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
    Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
    Lennox JL
    Curr Opin HIV AIDS; 2012 Sep; 7(5):409-14. PubMed ID: 22789985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interactions between the human immunodeficiency virus and hepatitis C virus].
    Pol S; Zylberberg H
    Rev Med Interne; 1998 Dec; 19(12):885-91. PubMed ID: 9887456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic interventions for HIV infection and chronic viral hepatitis.
    Cooper CL
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S69-72. PubMed ID: 16265617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management.
    Kang W; Tong HI; Sun Y; Lu Y
    Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):247-66. PubMed ID: 24450362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.